Danaher Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong execution, with core revenue up 0.5% and adjusted EPS up 9.5% year-over-year. Bioprocessing and life sciences offset respiratory headwinds, and the Masimo acquisition is expected to be accretive. Full-year guidance was raised for adjusted EPS.
-
Guidance for 2026 targets 3%-6% growth, led by bioprocessing and improving life sciences, with high incremental margins supporting strong EPS and margin expansion. The Masimo acquisition is expected to be accretive, with significant cost and revenue synergies. Innovation in diagnostics and bioprocessing, along with a years-long CapEx cycle and robust China recovery, underpin a positive outlook.
-
Fourth quarter 2025 results are expected to surpass expectations, driven by strong bioprocessing and diagnostics performance. Secular growth drivers, innovation, and a robust M&A strategy position the business for 3%–6% core revenue growth and high single-digit EPS growth in 2026.
Fiscal Year 2025
-
Strong Q4 and full-year 2025 results featured robust bioprocessing growth, margin expansion, and record free cash flow. 2026 guidance calls for 3%-6% core revenue growth and $8.35-$8.50 EPS, with continued innovation and improving end markets expected to drive performance.
-
Q3 results exceeded expectations, supporting reinvestment for 2026, with core growth targeted at 3%-6% and high single-digit EPS growth. Bioprocessing consumables and diagnostics innovation drive segment strength, while China and M&A remain strategic priorities.
-
Q3 results exceeded expectations with strong bioprocessing and diagnostics growth, robust cash flow, and margin expansion. 2025 guidance is maintained, with 2026 outlook for 3–6% core revenue growth and high single-digit EPS growth, supported by productivity initiatives and resilient end markets.
-
Q2 saw solid results with $5.9B in sales, 1.5% core revenue growth, and a 5% EPS increase. Bioprocessing led with high single-digit growth, while diagnostics and life sciences showed mixed trends. Full-year guidance was raised, but trade and policy uncertainties remain.
-
Strong bioprocessing growth and robust cost management are driving improved full-year guidance. Tariff mitigation, global manufacturing flexibility, and a focus on M&A position the business for long-term growth, despite near-term headwinds in China and academic funding.
-
The meeting covered director elections, auditor appointment, and executive compensation, with all proposals passing by large majorities. No shareholder proposals were introduced, and the formal business concluded efficiently.
-
Q1 2025 results exceeded expectations with strong bioprocessing and respiratory demand. Full-year core revenue growth is expected at 3% and adjusted EPS at $7.60–$7.75, with tariffs and soft U.S. academic demand as key risks. Bioprocessing and M&A remain strategic priorities.
-
2024 ended with a return to growth, and 2025 is set as a recovery year with cost reductions and a focus on margin expansion. Bioprocessing and diagnostics are driving growth, while innovation and strategic M&A remain priorities. Long-term growth and margin targets are reaffirmed.
-
Fourth quarter 2024 results exceeded expectations, driven by strong bioprocessing and diagnostics performance, with recurring revenue now at 80%. Portfolio transformation and innovation have positioned the company for high single-digit long-term growth, while China stabilizes at lower activity. M&A remains a strategic focus, and the company is confident in its ability to deliver sustainable value.
Fiscal Year 2024
-
2024 ended with strong bioprocessing and life sciences momentum, solid cash flow, and margin expansion. 2025 guidance anticipates 3% core revenue growth, with bioprocessing expected to deliver 6%-7% growth and diagnostics facing headwinds from VBP and respiratory normalization.
-
Q3 outperformed expectations, with strong bioprocessing and diagnostics growth. Large customers are driving recovery, while China remains subdued due to funding constraints. Diagnostics innovation and segment expansion support long-term growth, with margin improvement expected to be gradual.
-
Q3 2024 saw revenue, adjusted EPS, and cash flow exceed expectations, driven by bioprocessing momentum and strong Cepheid results. Life sciences and diagnostics showed mixed trends, with China and smaller bioprocessing customers remaining weak. Guidance for 2024 is unchanged.
-
Diagnostics is positioned for long-term high single-digit growth, driven by innovation, expanded product offerings, and secular healthcare trends. Beckman Coulter and Cepheid are accelerating growth through new product launches and menu expansion, while platform synergies and targeted M&A support future opportunities.
-
Q2 2024 results exceeded expectations with strong bioprocessing and diagnostics performance, despite a 3.5% core revenue decline. Guidance for 2024 remains unchanged, with bioprocessing expected to return to high single-digit growth by year-end.